Mizuho Securities analyst Salim Syed maintained a Buy rating on Wave Life Sciences (WVE) today and set a price target of $19.00. The company’s shares closed last Thursday at $8.77, close to its 52-week low of $6.61.
According to TipRanks.com, Syed has 0 stars on 0-5 stars ranking scale with an average return of -7.2% and a 45.2% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Coherus Biosciences, and BridgeBio Pharma.
Currently, the analyst consensus on Wave Life Sciences is a Moderate Buy with an average price target of $17.20.
See today’s analyst top recommended stocks >>
The company has a one-year high of $39.98 and a one-year low of $6.61. Currently, Wave Life Sciences has an average volume of 1.27M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
